High Titer Inhibitors in Severe Haemophilia A

E Briët; F R Rosendaal; W Kreuz; V Rasi; K Peerlinck; J Vermylen; R Ljung; A Rocino; J Addiego; J I Lorenzo; I Pabinger

doi:10.1055/s-0038-1648832

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1994; 72(01): 162-164
DOI: 10.1055/s-0038-1648832

Letter to the Editor

Schattauer GmbH Stuttgart

High Titer Inhibitors in Severe Haemophilia A

A Meta-analysis Based on Eight Long-term Follow-up Studies concerning Inhibitors Associated with Crude or Intermediate Purity Factor VIII Products

E Briët

Leiden, The Netherlands

,

F R Rosendaal

Leiden, The Netherlands

,

W Kreuz

Frankfurt, Germany

,

V Rasi

Helsinki, Finland

,

K Peerlinck

Leuven, Belgium

,

J Vermylen

Leuven, Belgium

,

R Ljung

Malmö, Sweden

,

A Rocino

Naples, Italy

,

J Addiego

Oakland, CA, USA

,

J I Lorenzo

Valencia, Spain

,

I Pabinger

Vienna, Austria

› Institutsangaben

Abstract

als PDF herunterladen

PDF (236 kb)

Referenzen

References
1 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. and the Kogenate Previously Untreated Patient Group Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - Safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453-459
2 Bray GL, Courter SG, Lynes M, Lee M, Gomperts E. and the Recombinate Study Group Safety, efficacy and inhibitor risk of recombinant factor VIII (Recombinate) in a cohort of previously untreated patients (PUP’s) with severe hemophilia. Thromb Haemost 1993; 69: 1205 (Abstract)
3 Peerlinck K, Amout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-118
4 Rosendaal FR, Nieuwenhuis HK, Van den Berg HM. et al A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-2186
5 Lusher JM, Salzman PM. Monoclate study group Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin He-matol 1990; 27 Suppl (Suppl. 02) 1-7
6 Addiego Jr JE, Gomperts E, Liu S-L. et al Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIC immuno-affinity chromatography. Thromb Haemost 1992; 67: 19-27
7 Schwarzinger I, Pabinger I, Kominger C. et al Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24: 241-245
8 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371
9 Ehrenforth S, Kreuz W, Scharrer I. et al Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
10 Lorenzo JI, Garcia R, Molina R. Factor VIII and factor IX inhibitors in haemophiliacs (Letter to the Editor). Lancet 1992; 339: 1550-1551
11 Ljung R, Petrini P, Lindgren A-C, Tengbom L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs (Letter to the Editor). Lancet 1992; 339: 1550
12 De Biasi R, Rocino A, Papa ML, Salerno E. Incidence of inhibitors in hemophilia A patients. Thromb Haemost 1993; 69: 1103 (Abstract)
13 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-3335
14 Addiego JE, Kasper CK, Abildgaard C. et al Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-464
15 Vermylen J, Briët E. Factor VIII preparations: Need for prospective pharmacovigilance. Lancet 1993; 342: 693-694